Genzyme Europe

Company snapshot

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Genzyme Europe. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Genzyme Europe.

1. Jun 8, 2026 Clinical update

   EFC16035 — Phase 3

2. Jun 8, 2026 Clinical update

   PDY13949 — Phase 2

3. Jun 8, 2026 Clinical update

   LTE15174 — Phase 3

4. Jun 8, 2026 Clinical update

   EFC13738 — Phase 3

5. May 26, 2026 Clinical update

   SAR439774 — Phase 3

View all clinical trial activity →

• What is Genzyme Europe?

  Genzyme Europe is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hemophilia, Gaucher's disease type I; Gaucher's disease type III, Primary Progressive Multiple Sclerosis, Hemophilia A or Hemophilia B, Gaucher disease type 3, Gaucher disease typ

• Is Genzyme Europe publicly traded?

  Genzyme Europe appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Genzyme Europe develop or market?

  We link 10 drug profile(s) where Genzyme Europe is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/genzyme-europe-b-v#company-drugs.

• What are the latest developments for Genzyme Europe?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Genzyme Europe focus on?

  Genzyme Europe focuses on Hemophilia, Gaucher's disease type I; Gaucher's disease type III, Primary Progressive Multiple Sclerosis based on our analysis of their pipeline programs and drug development activities.